Introduction
Osteoporosis is a disease in which bone mass and strength is reduced over time, increasing bone fragility and leading to more frequent fractures. 1 Osteoporosis affects 10 million people in the United States, and another 33.6 million have low bone mass. 2 Risk of osteoporosis increases with age and is greater in women than men; therefore, screening of at-risk populations is critical. 2 The gold standard for measuring and diagnosing conditions of low bone density is a dual-energy xray absorptiometry (DXA) scan. Evaluation of bone mineral density (BMD) with a DXA scan is recommended for women older than 65 years and men older than 70 years, adults with
Corresponding author: Jean-Venable R. Goode, PharmD, BCPS, FAPhA, FCCP; Virginia Commonwealth University School of Pharmacy, Richmond, VA. Email: jrgoode@vcu.edu a fracture after 50 years, and anyone older than 50 years with risk factors for low bone mass. 1, 2 Osteoporosis can be treated with prescription medications and nonprescription calcium supplements, and it can also be prevented. Maintaining adequate calcium and vitamin D intake, performing proper weight-bearing exercise, and not smoking or consuming excessive alcohol are important for prevention of the disease. 2 The National Osteoporosis Foundation (NOF) recommends that all women be informed of the risk factors for osteoporosis, because early screening and proper preventive measures are critical to avoid fractures. 1 This call for a wellinformed population warrants a community-based screening and education program targeting women and girls of all ages. Community pharmacists, as highly accessible health care providers, have effectively screened patients using heel ultrasonometers and used the results to provide education and to refer high-risk patients to physicians for further evaluation and management. [4] [5] [6] [7] Patients participating in osteoporosis screening services conducted by community pharmacists were satisfied with the service. [8] [9] Several studies evaluated the effect pharmacist-provided osteoporosis screenings had on patient behaviors, such as discussing their screening result with a physician or taking calcium supplements. These studies found that pharmacist intervention resulted in favorable behaviors. 4, [10] [11] [12] [13] However, the literature does not contain studies that evaluate the impact of pharmacist-provided screening and education on women's knowledge of osteoporosis or strategies for prevention. Increasing patient knowledge of osteoporosis and preventive strategies may provide the tools to prevent the disease and improve bone mass.
Objective
The objective of this study was to evaluate the impact pharmacist-provided osteoporosis screening and education has on patient knowledge of osteoporosis and strategies for prevention. The knowledge portion of the survey (Appendix A) was developed using the NOF guidelines as a foundation. According to these guidelines, all women should be aware of adequate calcium and vitamin D intake, physical activity, tobacco and alcohol cessation as prevention strategies for osteoporosis. 1 Basic pathophysiology, major risk factors, and long-term risks of osteoporosis were also identified as important items for the survey. 1 In addition, national recommendations for screening of women were selected for inclusion. [1] [2] [3] Once developed and agreed upon by all authors, the survey was pretested with a group of patients for content and clarity.
Methods
The survey contained ten questions that evaluated knowledge of osteoporosis, characteristics that predispose people to the disease, the appropriate age for testing, and knowledge of preventive strategies, including weight-bearing exercise, adequate consumption of calcium and vitamin D, and sources of these nutrients. Each knowledge survey item was assigned one of the following categories: osteoporosis knowledge, knowledge of risk factors, preventive strategies, and appropriate age for osteoporosis testing.
Screening sessions were advertised to customers of the supermarket and pharmacy using fliers throughout the store and employees' verbal referral at the prescription point of sale. Patients were able to schedule appointments via telephone, however; patients did not have to have an appointment to attend the screening session. Patients selfselected into the study by agreeing to the bone density screening and completing the knowledge survey. The inclusion criteria were female gender, age ≥30 years, and a medical history absent of osteoporosis. However, all women interested in the screening and education session were provided the service, regardless of whether they agreed to participate in the study.
Patients were randomized using a random number table containing a list of 250 entries of either 1 or 2. The primary author generated the table prior to the first screening, and each patient was randomized into Group A or Group B, as indicated by the table (1=Group A; 2=Group B). Group A took the knowledge survey before the screening and education service was provided by the pharmacist. Group B received the screening and education service provided by the pharmacist, followed by the knowledge survey. Patients were not asked to complete the knowledge survey both preand post-intervention, since the time points would have been too close together for adequate evaluation in one patient.
The primary author conducted all of the screening sessions which were approximately 15 minutes and included screening with the Achilles Express heel ultrasonometer, education, and survey completion. 14 Standardized verbal education was provided and included information about the result of the heel scan and osteoporosis. Osteoporosis information was obtained from multiple sources and included the following; general osteoporosis description, characteristics that predispose people to the disease, the appropriate age for testing, and common preventive strategies. [1] [2] [3] No patients who were screened and received education paid for the service, regardless of whether they chose to complete the survey.
The knowledge survey was scored by the primary author. Each survey item was marked correct or incorrect, with fractional scores assessed for multi-part questions. Each item in Group A was compared to Group B using t-tests both in each category as well as for overall score. Subsequently, each group was stratified into risk category groups, as indicated by their screening results. Low-risk and moderate-risk subgroups were analyzed using t-tests to detect differences in knowledge scores between the subgroups.
Results
A total of 110 women were enrolled in the study, screened for risk of future fractures, provided education, and surveyed for their knowledge. There were no significant differences in baseline demographics observed. The mean (±SD) age was 52.5 ± 13.1 years in Group A (n=52) and 52.7 ± 11.4 years in Group B (n=58). Demographics for patients were selfreported (see Table 1 ). Performance on the knowledge survey improved in all categories in the group taking the survey after pharmacist education. Total score, or overall knowledge, also improved in the group who received pharmacist education before the survey (Figure 1 ).
When each group was stratified into those at low risk of future fractures and those who had moderate risk of future fractures, knowledge scores were similar. In Group A, overall knowledge score was 44.5% for those at low risk and 38.4% in those at moderate risk (p = 0.207). In Group B, overall knowledge score was 77.7% for those at low risk and 73.6% for those at moderate risk (p = 0.775).
Discussion
The literature contains studies which show that pharmacists are capable of screening, educating, and referring patients at risk for osteoporosis in the community setting. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] In this study and previous studies, the education provided by pharmacists included an overview of osteoporosis, appropriate calcium and vitamin D intake, lifestyle measures for prevention (i.e. weight-bearing exercise, smoking cessation), and results from screenings performed.
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Previous studies also included additional topics for patient education which are most appropriate when targeting an elderly population or a population already diagnosed with osteoporosis, like home safety and medications for treatment. 6, 7 The duration of the education sessions in this study was appropriate, based on the previous literature citing education sessions between 10 and 20 minutes. 5, 6, 10, 13 However, the literature is absent of studies evaluating the impact of a pharmacist provided osteoporosis screening and education service on patient knowledge. This study demonstrated the pharmacist's ability to screen women for risk of future fractures and provide focused education within a 15-20 minute session. Furthermore, the results demonstrated that patient knowledge of the disease, risk factors, preventive measures, and age for testing increased after pharmacist intervention. Patient knowledge of risk level, risk factors, and preventive measures have been associated with positive lifestyle modifications and lower fall risk, which may, in turn, augment fracture risk. [15] [16] [17] [18] Patients screened in this study had an average age of 52.6 years consistent with other studies with similar inclusion criteria, ages ranging from 47.5 to 59.6 years. 4, 5, 10, 12 Bone mass loss accelerates after menopause, and screening and educating patients prior to this time is a best practice to avoid disease. 1, 2 The fact that mean age fell toward the low end of this range may be accounted for by the inclusion criterion of a medical history absent of osteoporosis.
The largest improvement in knowledge was seen with the question that addressed the age by which all women should receive testing for osteoporosis, 6.9% in Group A and 69% in Group B (p<0.001). This data shows that there is a deficit in women's knowledge about appropriate age for osteoporosis 
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testing. Pharmacists providing this information to patients may help increase the number of women being screened for this disease at the age recommended in the NOF guidelines. 1 In Group A, a larger proportion (26.9%) of patients reported to be healthcare professionals than in Group B (19%). The proportion of patients who reported being healthcare professionals was larger in the group who took the survey at baseline, which supported the result that the pharmacist intervention improved knowledge despite a potential for higher baseline knowledge. However, all patients selfselected into the study, which may have meant that they were generally more health conscious and may have had higher baseline knowledge than the general public. The statistically significant increase in knowledge between groups indicates that the pharmacist intervention was effective despite this issue, but results may not be generalizable to the whole population.
The results of this study did not indicate that there was a significant difference between knowledge of patients with low risk of future fractures and those with moderate risk of future fractures (A: p=0.207; B: p=0.775). However, there was a very small sample size of patients at moderate risk of future fractures, and this study was not designed to evaluate this endpoint. Numerically, scores were lower in patients at moderate risk of future fractures (Group A: 44.5% vs. 38.4%; Group B: 77.7% vs. 73.6%). No study patients fell into the high risk category, which may be because the inclusion criteria stated patients should have a self-reported medical history absent of osteoporosis. Some previous studies in community pharmacies focused on the older women or postmenopausal women only, which would likely result in more patients in the higher risk categories. [6] [7] [8] 11, 13 Other studies that did not focus on women of older age allowed inclusion of women with diagnosed osteoporosis, which would also increase the number of high-risk scan results. [4] [5] 10 The pharmacist is a highly accessible health care provider who can serve as an effective advocate for screening, treatment, and education for osteoporosis. As community pharmacists' role in healthcare evolves, the education they are capable of providing to patients may be used to contribute to better bone health outcomes and lower healthcare costs overall.
Limitations
The most significant limitation to this study was that the knowledge survey used was not validated. In addition, patients self-selected into the pharmacist provided screening and education service. Patients likely to self-select into the study may be more health conscious overall, which may skew the results of their scans and knowledge survey results compared to the general population. Demographic data collected was also based on patient self-report. Finally, the knowledge survey was administered immediately following the pharmacist-provided screening and education. Ideally, the knowledge would have been evaluated in a follow-up several weeks later, to better evaluate retention of knowledge. This would likely be better linked to prevention of disease, since knowledge retained would have a greater impact if employed over time (e.g. weight-bearing exercise, calcium and vitamin D supplementation).
Conclusions
Community pharmacist-provided osteoporosis screening and education increased patient knowledge about osteoporosis, its risk factors, its preventive strategies, and the age by which women should be tested. Further studies that evaluate knowledge retained after a community screening and education service are warranted. 
